TCRX vs. FATE, VYGR, ABSI, NKTX, ADPT, NMRA, VIR, BCRX, CGEM, and TARS
Should you be buying TScan Therapeutics stock or one of its competitors? The main competitors of TScan Therapeutics include Fate Therapeutics (FATE), Voyager Therapeutics (VYGR), Absci (ABSI), Nkarta (NKTX), Adaptive Biotechnologies (ADPT), Neumora Therapeutics (NMRA), Vir Biotechnology (VIR), BioCryst Pharmaceuticals (BCRX), Cullinan Therapeutics (CGEM), and Tarsus Pharmaceuticals (TARS). These companies are all part of the "medical" sector.
TScan Therapeutics (NASDAQ:TCRX) and Fate Therapeutics (NASDAQ:FATE) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their analyst recommendations, community ranking, risk, institutional ownership, profitability, earnings, media sentiment, dividends and valuation.
TScan Therapeutics has a net margin of -653.50% compared to Fate Therapeutics' net margin of -2,933.79%. Fate Therapeutics' return on equity of -46.49% beat TScan Therapeutics' return on equity.
TScan Therapeutics has a beta of 0.91, suggesting that its stock price is 9% less volatile than the S&P 500. Comparatively, Fate Therapeutics has a beta of 1.8, suggesting that its stock price is 80% more volatile than the S&P 500.
82.8% of TScan Therapeutics shares are owned by institutional investors. Comparatively, 97.5% of Fate Therapeutics shares are owned by institutional investors. 2.8% of TScan Therapeutics shares are owned by company insiders. Comparatively, 5.0% of Fate Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.
TScan Therapeutics presently has a consensus target price of $12.00, suggesting a potential upside of 40.35%. Fate Therapeutics has a consensus target price of $6.58, suggesting a potential upside of 78.89%. Given Fate Therapeutics' higher probable upside, analysts plainly believe Fate Therapeutics is more favorable than TScan Therapeutics.
TScan Therapeutics has higher revenue and earnings than Fate Therapeutics. TScan Therapeutics is trading at a lower price-to-earnings ratio than Fate Therapeutics, indicating that it is currently the more affordable of the two stocks.
Fate Therapeutics received 456 more outperform votes than TScan Therapeutics when rated by MarketBeat users. However, 74.19% of users gave TScan Therapeutics an outperform vote while only 68.62% of users gave Fate Therapeutics an outperform vote.
In the previous week, TScan Therapeutics had 3 more articles in the media than Fate Therapeutics. MarketBeat recorded 7 mentions for TScan Therapeutics and 4 mentions for Fate Therapeutics. Fate Therapeutics' average media sentiment score of 0.48 beat TScan Therapeutics' score of 0.29 indicating that Fate Therapeutics is being referred to more favorably in the news media.
Summary
Fate Therapeutics beats TScan Therapeutics on 10 of the 18 factors compared between the two stocks.
Get TScan Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for TCRX and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding TCRX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
TScan Therapeutics Competitors List
Related Companies and Tools
